[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adma Biologics (ADMA)

Adma Biologics (ADMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,018,743
  • Shares Outstanding, K 231,773
  • Annual Sales, $ 510,170 K
  • Annual Income, $ 146,930 K
  • EBIT $ 215 M
  • EBITDA $ 224 M
  • 60-Month Beta 0.73
  • Price/Sales 4.00
  • Price/Cash Flow 13.47
  • Price/Book 5.24

Options Overview Details

View History
  • Implied Volatility 73.14% (+0.42%)
  • Historical Volatility 32.31%
  • IV Percentile 71%
  • IV Rank 31.13%
  • IV High 147.60% on 03/27/26
  • IV Low 39.48% on 01/22/26
  • Expected Move (DTE 34) 1.32 (15.13%)
  • Put/Call Vol Ratio 33.20
  • Today's Volume 4,515
  • Volume Avg (30-Day) 692
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 73,495
  • Open Int (30-Day) 74,356
  • Expected Range 7.39 to 10.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.16
  • Number of Estimates 1
  • High Estimate $0.16
  • Low Estimate $0.16
  • Prior Year $0.15
  • Growth Rate Est. (year over year) +6.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.23 +5.83%
on 06/29/26
9.33 -6.65%
on 07/10/26
+0.29 (+3.44%)
since 06/17/26
3-Month
7.45 +16.91%
on 06/02/26
11.42 -23.73%
on 04/24/26
-2.30 (-20.89%)
since 04/17/26
52-Week
7.21 +20.80%
on 03/26/26
20.46 -57.42%
on 12/12/25
-8.88 (-50.48%)
since 07/17/25

Most Recent Stories

More News
ADMA Deadline: ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

NEW YORK , July 17, 2026 /PRNewswire/ -- 

ADMA : 8.71 (-1.14%)
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

NEW YORK and NEW ORLEANS , July 17, 2026 /PRNewswire/ --  Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ...

ADMA : 8.71 (-1.14%)
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 17, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors...

ADMA : 8.71 (-1.14%)
ADMA Biologics, Inc. Stock Drop: Robbins LLP Urges Investors to Contact the Firm for Information About the Class Action Against ADMA Biologics, Inc.

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9, 2024...

ADMA : 8.71 (-1.14%)
ADMA INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead ADMA Biologics Class Action Lawsuit

SAN DIEGO , July 17, 2026 /PRNewswire/ --  Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities...

ADMA : 8.71 (-1.14%)
NASDAQ: ADMA CLASS ACTION NOTICE: Berger Montague Encourages ADMA Biologics, Inc. (NASDAQ: ADMA) Investors to Inquire About a Securities Fraud Class Action

PHILADELPHIA , July 16, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC  announces a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA)  ("ADMA" or the...

ADMA : 8.71 (-1.14%)
ADMA DEADLINE: SueWallSt Reminds ADMA BIOLOGICS, INC. Investors of Upcoming Securities Class Action Deadline

ADMA Biologics allegedly certified internal controls as effective while concealing channel stuffing and an undisclosed related party distributor operating from company headquarters.

ADMA : 8.71 (-1.14%)
ADMA DEADLINE: SueWallSt Reminds ADMA BIOLOGICS, INC. Investors of Upcoming Securities Class Action Deadline

ADMA Biologics allegedly certified internal controls as effective while concealing channel stuffing and an undisclosed related party distributor operating from company headquarters.

ADMA : 8.71 (-1.14%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines - ADMA

NEW YORK , July 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA).  Such investors...

ADMA : 8.71 (-1.14%)
ADMA Fraud Notice: ADMA Biologics Investors are Reminded to Contact BFA Law about the Filed Securities Fraud Class Action Lawsuit to Recover Investment Losses

A securities fraud class action lawsuit has been filed on behalf of ADMA Biologics investors after its stock plummeted 29% due to Culper Research channel stuffing claims, potentially violating federal...

ADMA : 8.71 (-1.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying...

See More

Key Turning Points

3rd Resistance Point 9.17
2nd Resistance Point 9.06
1st Resistance Point 8.88
Last Price 8.71
1st Support Level 8.59
2nd Support Level 8.48
3rd Support Level 8.30

See More

52-Week High 20.46
Fibonacci 61.8% 15.40
Fibonacci 50% 13.83
Fibonacci 38.2% 12.27
Last Price 8.71
52-Week Low 7.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.